Home > Research > Publications & Outputs > Planning multi-arm screening studies within the...
View graph of relations

Planning multi-arm screening studies within the context of a drug development programme

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Planning multi-arm screening studies within the context of a drug development programme. / Wason, James; Jaki, Thomas; Stallard, Nigel.
In: Statistics in Medicine, Vol. 32, No. 20, 10.09.2013, p. 3424-3435.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Wason, J, Jaki, T & Stallard, N 2013, 'Planning multi-arm screening studies within the context of a drug development programme', Statistics in Medicine, vol. 32, no. 20, pp. 3424-3435. https://doi.org/10.1002/sim.5787

APA

Vancouver

Wason J, Jaki T, Stallard N. Planning multi-arm screening studies within the context of a drug development programme. Statistics in Medicine. 2013 Sept 10;32(20):3424-3435. Epub 2013 Mar 26. doi: 10.1002/sim.5787

Author

Wason, James ; Jaki, Thomas ; Stallard, Nigel. / Planning multi-arm screening studies within the context of a drug development programme. In: Statistics in Medicine. 2013 ; Vol. 32, No. 20. pp. 3424-3435.

Bibtex

@article{314affd450324ebdb1f21c13a4e3b73f,
title = "Planning multi-arm screening studies within the context of a drug development programme",
abstract = "Screening trials are small trials used to decide whether an intervention is sufficiently promising to warrant a large confirmatory trial. Previous literature examined the situation where treatments are tested sequentially until one is considered sufficiently promising to take forward to a confirmatory trial. An important consideration for sponsors of clinical trials is how screening trials should be planned to maximize the efficiency of the drug development process. It has been found previously that small screening trials are generally the most efficient. In this paper we consider the design of screening trials in which multiple new treatments are tested simultaneously. We derive analytic formulae for the expected number of patients until a successful treatment is found, and propose methodology to search for the optimal number of treatments, and optimal sample size per treatment. We compare designs in which only the best treatment proceeds to a confirmatory trial and designs in which multiple treatments may proceed to a multi-arm confirmatory trial. We find that inclusion of a large number of treatments in the screening trial is optimal when only one treatment can proceed, and a smaller number of treatments is optimal when more than one can proceed. The designs we investigate are compared on a real-life set of screening designs. ",
keywords = "multi-arm multi-stage trials, optimal design , phase II trials , screening trials",
author = "James Wason and Thomas Jaki and Nigel Stallard",
year = "2013",
month = sep,
day = "10",
doi = "10.1002/sim.5787",
language = "English",
volume = "32",
pages = "3424--3435",
journal = "Statistics in Medicine",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",
number = "20",

}

RIS

TY - JOUR

T1 - Planning multi-arm screening studies within the context of a drug development programme

AU - Wason, James

AU - Jaki, Thomas

AU - Stallard, Nigel

PY - 2013/9/10

Y1 - 2013/9/10

N2 - Screening trials are small trials used to decide whether an intervention is sufficiently promising to warrant a large confirmatory trial. Previous literature examined the situation where treatments are tested sequentially until one is considered sufficiently promising to take forward to a confirmatory trial. An important consideration for sponsors of clinical trials is how screening trials should be planned to maximize the efficiency of the drug development process. It has been found previously that small screening trials are generally the most efficient. In this paper we consider the design of screening trials in which multiple new treatments are tested simultaneously. We derive analytic formulae for the expected number of patients until a successful treatment is found, and propose methodology to search for the optimal number of treatments, and optimal sample size per treatment. We compare designs in which only the best treatment proceeds to a confirmatory trial and designs in which multiple treatments may proceed to a multi-arm confirmatory trial. We find that inclusion of a large number of treatments in the screening trial is optimal when only one treatment can proceed, and a smaller number of treatments is optimal when more than one can proceed. The designs we investigate are compared on a real-life set of screening designs.

AB - Screening trials are small trials used to decide whether an intervention is sufficiently promising to warrant a large confirmatory trial. Previous literature examined the situation where treatments are tested sequentially until one is considered sufficiently promising to take forward to a confirmatory trial. An important consideration for sponsors of clinical trials is how screening trials should be planned to maximize the efficiency of the drug development process. It has been found previously that small screening trials are generally the most efficient. In this paper we consider the design of screening trials in which multiple new treatments are tested simultaneously. We derive analytic formulae for the expected number of patients until a successful treatment is found, and propose methodology to search for the optimal number of treatments, and optimal sample size per treatment. We compare designs in which only the best treatment proceeds to a confirmatory trial and designs in which multiple treatments may proceed to a multi-arm confirmatory trial. We find that inclusion of a large number of treatments in the screening trial is optimal when only one treatment can proceed, and a smaller number of treatments is optimal when more than one can proceed. The designs we investigate are compared on a real-life set of screening designs.

KW - multi-arm multi-stage trials

KW - optimal design

KW - phase II trials

KW - screening trials

U2 - 10.1002/sim.5787

DO - 10.1002/sim.5787

M3 - Journal article

VL - 32

SP - 3424

EP - 3435

JO - Statistics in Medicine

JF - Statistics in Medicine

SN - 0277-6715

IS - 20

ER -